基本信息
views: 145
Career Trajectory
Bio
Dr. LAU is a successful pharmaceutical executive who has had extensive leadership experience in both scientific and business management. As Chairman and CEO of Ribapharm, he launched the second largest biotech IPO in US history ($300 million). During his tenure at Ribapharm, he met or exceeded Wall Street expectations each and every quarter. Prior to Ribapharm, he served as the Head of Worldwide Research and Development for ICN Pharmaceuticals.
Research Interests
Papers共 234 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
SPINE DEFORMITYno. 6 (2023): 1347-1354
Murray J. Cutler, Krista E. Belko,Yahao Bu, Alissa R. Verone-Boyle,David Cutler,Wing-Kai Chan,Rudolf Kwan,Johnson Y. Lau,Michael P. Smolinski
Murray Cutler, Belko Krista Elizabeth,Yahao Bu, Verone-Boyle Alissa Rae,David M. Cutler,Wing-Kai Chan,Rudolf Kwan,Johnson Y.N. Lau,Michael Smolinski
Cancer Research (2019): 4717-4717
Protein expression and purification (2018): 69-77
Kuo-Ming Yu,Johnson Yiu-Nam Lau,Manson Fok,Yuk-Keung Yeung,Siu-Ping Fok,Suxing Zhang,Peizhen Ye, Kezhi Zhang,Xiaobo Li, Juan Li,Qin Xu,Wing-Tak Wong,
M. -F. Yuen, K. Liu,B. Given,T. Schluep,J. Hamilton,C. L. Lai,S. Locarnini, K. Jackson,J. Y. Lau,C. Ferrari,R. G. Gish
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn